Literature DB >> 34288814

Circular RNA MAT2B promotes migration, invasion and epithelial-mesenchymal transition of non-small cell lung cancer cells by sponging miR-431.

Hui Wang1,2, Li Feng3, Deyun Cheng1, Yuqiong Zheng2, Yimin Xie4, Bing Fu5.   

Abstract

Circular RNAs (circRNAs) have recently been described as key regulators in the progression of non-small cell lung cancer (NSCLC), and this study aimed to investigate the functional role of circMAT2B in NSCLC. CircMAT2B expression in NSCLC tissues and cell lines was investigated using RT-qPCR analysis. A series of functional experiments, including MTT assay, colony formation assay, wound healing assay and transwell assay, were carried out to investigate the effects of circMAT2B knockdown/overexpression on the malignant traits of NSCLC cells. Western blot analysis was performed to detect the expression of EMT-related proteins. Dual-luciferase reporter assay and RIP assay were further carried out to analyze the interaction between circMAT2B and miR-431 in NSCLC. We observed that circMAT2B was overexpressed in NSCLC tissues and cell lines, and high expression of circMAT2B was closely associated with large tumor size, advanced TNM stage and poor prognosis of NSCLC patients. Further functional experiments showed that circMAT2B knockdown markedly inhibited the proliferation, migration, invasion and EMT of NSCLC cells, whereas circMAT2B overexpression led to the opposing results. Mechanistically, circMAT2B could directly interact with miR-431, and subsequently decrease miR-431 expression in NSCLC. The effects of circMAT2B overexpression in NSCLC cells were abrogated by miR-431 restoration. Our findings revealed the novel oncogenic roles of circMAT2B in NSCLC by sponging miR-431.

Entities:  

Keywords:  EMT; Non-small cell lung cancer; circular RNA MAT2B; miR-431; prognosis

Mesh:

Substances:

Year:  2021        PMID: 34288814      PMCID: PMC8409757          DOI: 10.1080/15384101.2021.1956106

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  18 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Circular RNA: A new star of noncoding RNAs.

Authors:  Shibin Qu; Xisheng Yang; Xiaolei Li; Jianlin Wang; Yuan Gao; Runze Shang; Wei Sun; Kefeng Dou; Haimin Li
Journal:  Cancer Lett       Date:  2015-06-05       Impact factor: 8.679

Review 3.  Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer.

Authors:  Chunyan Li; Lin Zhang; Guangping Meng; Qi Wang; Xuejiao Lv; Jie Zhang; Junyao Li
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-19       Impact factor: 4.553

4.  Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress.

Authors:  Qing Li; Xiongxiong Pan; Deming Zhu; Zhengming Deng; Runqiu Jiang; Xuehao Wang
Journal:  Hepatology       Date:  2019-05-28       Impact factor: 17.425

5.  MiR-431 suppresses proliferation and metastasis of lung cancer via down-regulating DDX5.

Authors:  C-M Xu; L-X Chen; F Gao; M-F Zhu; Y Dai; Y Xu; W-X Qian
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-01       Impact factor: 3.507

6.  Natural RNA circles function as efficient microRNA sponges.

Authors:  Thomas B Hansen; Trine I Jensen; Bettina H Clausen; Jesper B Bramsen; Bente Finsen; Christian K Damgaard; Jørgen Kjems
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

7.  ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.

Authors:  Jill E Larsen; Vaishnavi Nathan; Jihan K Osborne; Rebecca K Farrow; Dhruba Deb; James P Sullivan; Patrick D Dospoy; Alexander Augustyn; Suzie K Hight; Mitsuo Sato; Luc Girard; Carmen Behrens; Ignacio I Wistuba; Adi F Gazdar; Nicholas K Hayward; John D Minna
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

Review 8.  Circular RNA participates in the carcinogenesis and the malignant behavior of cancer.

Authors:  Zhen-Jun Zhao; Jun Shen
Journal:  RNA Biol       Date:  2015-12-09       Impact factor: 4.652

9.  Protease-activated receptor-2 induces expression of vascular endothelial growth factor and cyclooxygenase-2 via the mitogen-activated protein kinase pathway in gastric cancer cells.

Authors:  Cheng Zhang; Guang-Rong Gao; Chen-Guang Lv; Boa-Lei Zhang; Zhi-Li Zhang; Xue-Feng Zhang
Journal:  Oncol Rep       Date:  2012-08-30       Impact factor: 3.906

10.  The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p.

Authors:  Siliang Wei; Yuanyuan Zheng; Yanru Jiang; Xiaojun Li; Jian Geng; Yuanbing Shen; Qin Li; Xiaojing Wang; Chengling Zhao; Yuqing Chen; Zhongqing Qian; Jihong Zhou; Wei Li
Journal:  EBioMedicine       Date:  2019-05-31       Impact factor: 8.143

View more
  3 in total

1.  Microarray Identifies a Key Carcinogenic Circular RNA 0008594 That Is Related to Non-Small-Cell Lung Cancer Development and Lymph Node Metastasis and Promotes NSCLC Progression by Regulating the miR-760-Mediated PI3K/AKT and MEK/ERK Pathways.

Authors:  Qiushi Wang; Chunhua Yan; Pengfei Zhang; Guanghua Li; Ruidong Zhu; Hanbing Wang; Libo Wu; Guangquan Xu
Journal:  Front Oncol       Date:  2021-11-11       Impact factor: 6.244

Review 2.  Using ncRNAs as Tools in Cancer Diagnosis and Treatment-The Way towards Personalized Medicine to Improve Patients' Health.

Authors:  Roberto Piergentili; Giuseppe Basile; Cristina Nocella; Roberto Carnevale; Enrico Marinelli; Renato Patrone; Simona Zaami
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

3.  The pivotal regulatory factor circBRWD1 inhibits arsenic exposure-induced lung cancer occurrence by binding mRNA and regulating its stability.

Authors:  Xiaofei Li; Sixian Chen; Xin Wang; Ruirui Zhang; Jialei Yang; Haotian Xu; Wanting He; Mingshuang Lai; Shuilian Wu; Aruo Nan
Journal:  Mol Ther Oncolytics       Date:  2022-08-23       Impact factor: 6.311

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.